X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3503) 3503
Book Review (418) 418
Publication (113) 113
Book Chapter (6) 6
Magazine Article (6) 6
Conference Proceeding (5) 5
Book / eBook (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3230) 3230
humans (2661) 2661
male (1586) 1586
female (1517) 1517
antineoplastic combined chemotherapy protocols - therapeutic use (1278) 1278
middle aged (1269) 1269
uracil - administration & dosage (1189) 1189
aged (1141) 1141
tegafur - administration & dosage (1038) 1038
uracil - therapeutic use (987) 987
uracil - analogs & derivatives (930) 930
animals (870) 870
adult (865) 865
oncology (817) 817
administration, oral (473) 473
chemotherapy (460) 460
uracil (450) 450
drug combinations (445) 445
cancer (438) 438
pharmacology & pharmacy (438) 438
mice (418) 418
treatment outcome (417) 417
tegafur - therapeutic use (416) 416
5-fluorouracil (406) 406
fluorouracil - administration & dosage (404) 404
drug administration schedule (378) 378
aged, 80 and over (319) 319
leucovorin - administration & dosage (317) 317
fluorouracil (312) 312
antineoplastic combined chemotherapy protocols - administration & dosage (308) 308
antineoplastic combined chemotherapy protocols - adverse effects (298) 298
uracil - adverse effects (297) 297
combined modality therapy (296) 296
colorectal neoplasms - drug therapy (292) 292
chemotherapy, adjuvant (275) 275
uracil - pharmacology (265) 265
cisplatin - administration & dosage (264) 264
adenocarcinoma - drug therapy (259) 259
rats (253) 253
survival rate (252) 252
pyrimidines (230) 230
stomach neoplasms - drug therapy (230) 230
drug therapy, combination (229) 229
neoplasm staging (229) 229
fluorouracil - therapeutic use (228) 228
uft (223) 223
therapy (222) 222
antineoplastic agents - therapeutic use (217) 217
care and treatment (209) 209
uracils (209) 209
carcinoma (206) 206
radiotherapy (203) 203
colorectal cancer (197) 197
analysis (194) 194
surgery (189) 189
lung neoplasms - drug therapy (182) 182
patients (178) 178
research (176) 176
tegafur - adverse effects (176) 176
time factors (174) 174
antimetabolites, antineoplastic - therapeutic use (173) 173
liver neoplasms - drug therapy (170) 170
toxicity (169) 169
leucovorin (165) 165
prognosis (165) 165
radiology and nuclear medicine (157) 157
dose-response relationship, drug (156) 156
biochemistry & molecular biology (155) 155
colorectal neoplasms - pathology (154) 154
hematology, oncology and palliative medicine (152) 152
liver neoplasms - secondary (152) 152
radiology, nuclear medicine & medical imaging (152) 152
colonic neoplasms - drug therapy (145) 145
retrospective studies (145) 145
capecitabine (142) 142
diabetes mellitus, type 2 - drug therapy (142) 142
medicine & public health (141) 141
disease-free survival (140) 140
piperidines - therapeutic use (140) 140
uracil - metabolism (140) 140
medicine (137) 137
trial (136) 136
radiology (134) 134
prospective studies (131) 131
deoxycytidine - analogs & derivatives (130) 130
dna (129) 129
survival analysis (129) 129
stomach neoplasms - pathology (128) 128
uracil - pharmacokinetics (123) 123
drugs (122) 122
remission induction (122) 122
abridged index medicus (121) 121
tegafur (120) 120
health aspects (119) 119
antimetabolites, antineoplastic - administration & dosage (118) 118
follow-up studies (118) 118
lymphatic metastasis (118) 118
uracil - chemistry (118) 118
breast neoplasms - drug therapy (116) 116
clinical trials as topic (116) 116
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2508) 2508
Japanese (640) 640
Russian (253) 253
Italian (28) 28
German (24) 24
French (21) 21
Ukrainian (11) 11
Chinese (7) 7
Czech (7) 7
Spanish (4) 4
Polish (3) 3
Bulgarian (1) 1
Dutch (1) 1
Hungarian (1) 1
Norwegian (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
BMC Gastroenterology, ISSN 1471-230X, 08/2015, Volume 15, Issue 1, pp. 98 - 98
Background: The standard care of treatment of interferon plus ribavirin (plus protease inhibitor for genotype 1) are effective in 50 % to 70 % of patients with... 
Chronic hepatitis C | Olysio | Viekira Pak | Harvoni | Markov model | Cost-effectiveness | Sofosbuvir | UNITED-STATES | DIAGNOSIS | INTERFERON-ALPHA-2B | VIRUS-INFECTION | MANAGEMENT | RIBAVIRIN | COMPENSATED CIRRHOSIS | HEPATOCELLULAR-CARCINOMA | THERAPY | DISEASE | GASTROENTEROLOGY & HEPATOLOGY | Interferons - economics | Markov Chains | Fluorenes - economics | Ribavirin - economics | Humans | Middle Aged | Simeprevir - economics | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Ritonavir - economics | Male | Interferons - therapeutic use | Uridine Monophosphate - economics | Benzimidazoles - economics | Polyethylene Glycols - therapeutic use | Simeprevir - therapeutic use | Sofosbuvir - economics | Ritonavir - therapeutic use | Female | Macrocyclic Compounds - economics | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Quality-Adjusted Life Years | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Drug Therapy, Combination - economics | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Cost-Benefit Analysis | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Uracil - economics | Antiviral Agents - economics | Drug Combinations | Uracil - analogs & derivatives | Economic aspects | Markov processes | Hepatitis C virus | Analysis | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | CLINICAL-TRIALS | VASCULAR OUTCOMES | RISK | COMPLICATIONS | THERAPIES | CARDIOVASCULAR SAFETY | MELLITUS | BLOOD-GLUCOSE CONTROL | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article